The Liver Meeting
55th Annual Meeting of the American Association for the Study of
Liver Diseases

October 29 - November 2
Boston, Massachusetts
John B. Hynes Convention Center

 

 

Welcome to the HCV Advocate’s AASLD Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HCV related abstracts posted to www.aasld.org that we have not been able to report on or update.  

 

To locate specific abstracts on this page, click on “Edit” at the top of  your browser (Microsoft Internet Explorer) and then on Find (on this page).  In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.

 

Please click here to view our fact sheet on reading and understanding an abstract.

 

Thank You,

Alan Franciscus

Editor-in-Chief

 

 

 

 

 

 

Hepatitis C

 

Acute Hepatitis C - Treatment

 

Complementary Therapies-

·        COMPLEMENTARY AND ALTERNATIVE MEDICINE: A SURVEY FOR PEOPLE DIAGNOSED WITH HEPATITIS C

 

Cryoglobulinemia -

§        CENTRAL NERVOUS SYSTEM INVOLVEMENT IN HCV-CRYOGLOBULINEMIA VASCULITIS: A MULTICENTER CASE CONTROL STUDY USING MRI AND NEUROPSYCHOLOGICAL TESTS

Current Therapies-

Diabetes –

·        CAUSAL RELATIONSHIP BETWEEN HEPATITIS C VIRUS INFECTION AND THE DEVELOPMENT OF TYPE 2 DIABETES MELLITUS IN A HEPATITIS C VIRUS HYPERENDEMIC AREA

·        CHOLESTATIC LIVER ENZYMES AS PREDICTORS OF TYPE 2 DIABETES IN PATIENTS WITH HEPATITIS C INFECTION. A CROSS SECTIONAL STUDY (updated 10/31/2004)

 

Diagnostic Tools –

·        COMPARISON OF REAL TIME PCR (TAQMAN) ROCHE AND VERSANT HCV RNA BAYER FOR HCV RNA USING THE INTERNATIONAL UNIT STANDARD: IMPLICATIONS FOR MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION IN CLINICAL PRACTICE

·        DIAGNOSTIC VALUE OF BIOCHEMICAL MARKERS, FIBROTEST-ACTITEST-HCV-FIBROSURE (FT-AT) COMPARED WITH SERUM PROTEIN PROFILING BY SELDI-TOF PROTEINCHIP (STP), FOR THE DIAGNOSIS OF BRIDGING FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C

·        FIBROSCAN® IS A NEW NON INVASIVE METHOD FOR THE DETECTION OF CIRRHOSIS AND ITS COMPLICATIONS IN PATIENTS WITH CHRONIC LIVER DISEASES. RESULTS OF A PROSPECTIVE STUDY IN 456 PATIENTS  (updated 11/1/2004)

·        LARGE SCALE STUDIES USING NON-INVASIVE BIOCHEMICAL MARKERS OF LIVER INJURY, FIBROTEST-ACTITEST-HCV-FIBROSURE® (FT-AT): THE LOW NEGATIVE PREDICTIVE VALUE OF TRANSAMINASES IN AGED PATIENTS WITH CHRONIC HEPATITIS C  (updated 11/7/2004)

 

Disease Management

 

Disease Progression–

o       OBESITY PREDISPOSES TO ADVANCED LIVER DISEASE IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY

o       Steatosis

§        THE IMPACT OF DIABETES MELLITUS AND STEATOSIS ON HEPATIC FIBROSIS AND INFLAMMATION IN HCV PATIENTS

 

Epidemiology

 

Experimental Therapies–

 

Genotype–

 

Natural History–

 

Occult HCV–

 

Predicting Treatment Response–

 

Quality of Life–

 

Side Effect Management

 

Special Populations–

 

Transplantation

 

Treatment–

 

 

 

HIV/HCV Coinfection

 

Current Therapies-

 

 

Disease Progression–

 

Management Patterns-

 

Miscellaneous

 

Transplantation–

Treatment–